Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.49 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.45 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.45 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27137201 | 0.86 | PARP1 (0.53) | PARP1SMARCA2SMARCA4PBRM1 | |
| SCHEMBL26456085 | 0.85 | SMARCA2 (0.47) | GPR119SMARCA2SMARCA4PBRM1ABCB1 | |
| SCHEMBL30869214 | 0.85 | SMARCA2 (0.47) | PARP1GPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL25093589 | 0.85 | BACE1 (0.48) | PARP1GPR119BACE1 | |
| SCHEMBL24649831 | 0.77 | GPR119 (0.49) | PARP1GPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL24649920 | 0.77 | GPR119 (0.49) | PARP1GPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL24649965 | 0.77 | GPR119 (0.49) | PARP1GPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL29271658 | 0.76 | GPR119 (0.39) | PARP1GPR119BACE1 | |
| SCHEMBL29271666 | 0.76 | GPR119 (0.39) | PARP1GPR119BACE1 | |
| SCHEMBL29271660 | 0.76 | GPR119 (0.39) | PARP1GPR119BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4326720-A1 | PARP1 INHIBITORS AND USES THEREOF | Xinthera, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-117177972-A | PARP1 inhibitors and uses thereof | 新特拉有限公司 | 2023-12-05 | — | — | CN | disclosed |
| US-20230128041-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230128041-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-04-27 | — | — | US | disclosed |
| US-11591331-B2 | PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-11591331-B2 | PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220348574-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2022-11-03 | — | — | US | disclosed |
| WO-2022225934-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128041-A1 | PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | PARP1 1/4885GPR119 3965/4885SMARCA2 365/4885 |
| US-20220348574-A1 | PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | PARP1 1/4885GPR119 3965/4885SMARCA2 365/4885 |
| US-11591331-B2 | PARP1 inhibitors and uses thereof | PARP1, PARP11, PARP12 | PARP1 1/4885GPR119 3965/4885SMARCA2 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.